Pacific Biosciences of California
$ 1.19
1.72%
07 Aug - close price
- Market Cap 361,851,000 USD
- Current Price $ 1.19
- High / Low $ 1.23 / 1.17
- Stock P/E N/A
- Book Value 0.01
- EPS -0.37
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.12 %
- ROE -2.74 %
- 52 Week High 2.73
- 52 Week Low 1.09
About
Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to solve genetically complex problems. The company is headquartered in Menlo Park, California.
Analyst Target Price
$2.42
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-03 | 2026-05-07 | 2026-02-12 | 2025-11-05 | 2025-08-07 | 2025-05-08 | 2025-02-13 | 2024-11-07 | 2024-08-07 | 2024-05-09 | 2024-02-15 | 2023-10-30 |
| Reported EPS | -0.14 | -0.12 | -0.12 | -0.12 | -0.13 | -0.15 | -0.2 | -0.17 | -0.2 | -0.26 | -0.27 | -0.27 |
| Estimated EPS | -0.14 | -0.13 | -0.13 | -0.16 | -0.18 | -0.19 | -0.17 | -0.21 | -0.22 | -0.26 | -0.28 | -0.29 |
| Surprise | 0 | 0.01 | 0.01 | 0.04 | 0.05 | 0.04 | -0.03 | 0.04 | 0.02 | 0 | 0.01 | 0.02 |
| Surprise Percentage | 0% | 7.6923% | 7.6923% | 25% | 27.7778% | 21.0526% | -17.6471% | 19.0476% | 9.0909% | 0% | 3.5714% | 6.8966% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PACB
2026-08-06 18:40:56
TD Cowen has reiterated its Buy rating on Pacific Biosciences of California (PACB.US) and maintained its target price at $3. This indicates a continued positive outlook from the firm regarding the company's stock performance.
2026-08-06 16:40:55
PacBio reported an adjusted loss per share of 14 cents for Q2 2026, meeting estimates, but revenues of $39 million missed expectations and were down 2% year over year. The company reduced its 2026 revenue guidance to $155-$165 million due to weaker instrument sales, funding constraints in the Americas and Asia-Pacific, and slower-than-expected adoption of new chemistry. Despite challenges, PacBio highlighted growth in consumables revenue, strong clinical demand, and increased revenues in EMEA.
2026-08-06 07:40:57
PacBio has announced the appointment of Mark Van Oene as its new President and Chief Executive Officer, effective August 5, 2026. He succeeds Christian Henry, who led the company for six years and will remain on the Board and serve as a business advisor for a smooth transition. Van Oene, previously COO, has played a key role in advancing PacBio's operational execution, commercial strategy, product development, and AI-related initiatives, particularly focusing on expanding into clinical markets and AI-enabled product solutions.
2026-08-06 07:40:57
This article lists various ETFs that include Pacific Biosciences of California, Inc. (PACB) stocks in their holdings. It provides a detailed table for each ETF, including market value, weight, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volume, and 3-year NAV total return. The ETFs cover different investment strategies, such as thematic, small-cap, and healthcare-focused funds.
2026-08-06 05:41:43
Pacific Biosciences reported disappointing Q2 revenues of $39.01 million, missing estimates and lowering its 2026 revenue guidance below consensus. The company continues to face sizable operating and net losses, with cash reserves dwindling and significant debt outstanding. Despite trading at a steep discount to peers at 2.4x expected 2026 revenues, the outlook remains bleak due to weak financials and growth prospects.
2026-08-05 21:41:43
Pacific Biosciences (NASDAQ:PACB) reported a mixed Q2 2026, launching its SPRQ-Nx sequencing chemistry but missing revenue expectations and lowering full-year guidance. The company's stock declined following the announcement, as it also delayed its cash flow breakeven target to 2028. Despite clinical validation of its HiFi sequencing technology, PacBio faces challenges in translating product innovation into sustainable revenue growth amid funding uncertainties and the need for broader SPRQ-Nx adoption.
